Celldex Therapeutics Reports 98% Revenue Decline and $78.7 Million Net Loss in Q1 2026

Celldex Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $15.7 million, a significant decrease of 98% compared to $680,000 in the same period last year. The decline was primarily attributed to the absence of revenue from product development and licensing agreements, which had contributed $50,000 in the previous year. The company’s operating expenses rose to $84.5 million, up 33% from $63.4 million in the first quarter of 2025, driven largely by increased research and development costs associated with its lead product candidate, barzolvolimab.

The net loss for the quarter was $78.7 million, a 46% increase from the $53.8 million loss reported in the first quarter of 2025. This increase in net loss was primarily due to higher research and development expenses, which totaled $73 million, up 39% from $52.6 million a year earlier. The company noted that the rise in expenses was largely due to costs related to the ongoing clinical trials for barzolvolimab, which is being developed for various mast cell-driven diseases.

In terms of operational developments, Celldex has made significant progress in its clinical programs. The company completed enrollment in its Phase 3 studies for barzolvolimab in chronic spontaneous urticaria (CSU), with topline data expected in the fourth quarter of 2026. The Phase 3 studies represent the largest program conducted in antihistamine-refractory CSU, involving 1,939 patients across 43 countries. Additionally, the company has expanded its pipeline with the initiation of a Phase 1 study for its bispecific antibody candidate, CDX-622, which targets pathways involved in chronic inflammation.

As of March 31, 2026, Celldex reported cash, cash equivalents, and marketable securities totaling $451.5 million, a decrease from $582.9 million at the end of 2025. The company utilized $65.6 million in cash for operating activities during the quarter, compared to $54.4 million in the same period last year. The company anticipates that its current cash reserves, bolstered by a recent public offering that raised approximately $323.9 million in April 2026, will be sufficient to fund its operations through 2028. However, Celldex indicated that it may seek additional capital to support its long-term liquidity needs, which could include licensing agreements, debt issuance, or further equity offerings.

Looking ahead, Celldex remains focused on advancing its clinical programs and expanding its product pipeline. The company plans to continue its research and development efforts, particularly for barzolvolimab, while also exploring opportunities for strategic partnerships to enhance its financial position and operational capabilities.